Blog
These 3 Dividend Stocks Could Slash Their Payouts
Shareholders of Triangle Capital (NYSE: TCAP), Ares Capital (NASDAQ: ARCC), and Hercules Capital (NYSE: HTGC) should look at these stocks' sky-high yields with skepticism. As business-development
3 Ways You Could Damage Your Credit Score By Accident
Many behaviors that could be damaging to your credit are common knowledge, such as missing payments or maxing out a credit card. On the other hand, there are some credit-damaging behaviors that you
Gold Stocks for a Successful Trump Presidency
Billionaire investors like Jacob Rothschild, David Einhorn, and Ray Dalio are buying gold because they are concerned that President Donald Trump will upend the stock market. But what if they are wrong
3 Top Oil Stocks For July
Crude prices haven't behaved as expected this year, ending the first half down double digits and settling in the mid-$40s. That sell-off in the oil market has taken most oil stocks down with it
Why Is the US Selling Billions of Dollars of Missiles to Romania?
From the Romanian border to the Russian naval base at Sevastopol in occupied Crimea is a distance of less than 200 miles by boat (or warplane). A Su-27 fighter jet stationed in Moldova's breakaway
Which Gold Mining Stock Will Thrive No Matter What Happens?
Despite falling steadily since June, the price of gold is still up more than 7% year to date. And the upward movement may well continue as fear and volatility creep into the market in reaction to
Do These 3 Things Before You Start Investing
I've written many times before about the virtues of investing. In fact, I've gone so far as to say that if you fail to invest your money relatively early on in life, you could lose out on countless
5 Top Consumer-Discretionary ETFs
Consumers buy a lot of things, but it's the things they don't absolutely have to buy that go toward supporting the consumer-discretionary sector of the stock market. Some of the consumer goods that
Don't Make This Social Media Mistake While Job-Hunting
Many people use social media strictly for fun.Perhaps your Facebook (NASDAQ: FB) and Instagram are only for family and friends. Maybe you mostly use Twitter (NYSE: TWTR) as a news source and you may
3 Dividend Stocks Ideal for Your Golden Years
Let's face it: Not every stock is a good pick for you in your golden years. You don't want to be saddled with risky and volatile stocks. Instead, you need stable and steady stocks with solid business
Can I File for Medicare Without Social Security?
Medicare provides critical health benefits for millions of seniors 65 and over. Similarly, Social Security serves as a crucial source of income for countless retirees. And though the two often go hand
Do You Really Need $2.4 Million to Be Wealthy?
How much money would you have to have tucked away before you considered yourself wealthy? According to the most recent Charles Schwab Modern Wealth Index survey, Americans believe that they need at
4 Things Millennials Should Expect From Social Security
Social Security is, for millions of retired Americans, a financial lifeline that they simply couldn't do without. A 2017 Gallup poll found that a majority of seniors relies on their monthly benefits
Can I Contribute to an IRA If I Have a 401(k) at Work?
Having a 401(k) or similar employer-sponsored retirement can certainly be a nice tool to grow your nest egg, especially if your employer provides a generous matching contribution. Having said that
Family Office Exchange: 10 Things Wealthy Families Should Know
Many financially successful families have accumulated vast amounts of wealth through a variety of means, ranging from starting their own businesses to passing down legacies that have come from
3 Stocks That Turned $1,000 Into at Least $2,017 in 12 Months
Although there is some truth in the saying that it takes money to make money, that doesn't mean investors can't start small and reap big rewards. With little more than $1,000 in your account, you can
This Expense Could Cost You Over $86,000 in Retirement
When you think about retirement, you probably like to believe that the moment you leave work for good, everything will be smooth sailing for the rest of your days.In reality, however, life throws
Will Congress Let U.S. Newspapers Bargain Collectively With Google and Facebook?
In this Market Foolery segment, host Chris Hill and Motley Fool Rule Breakers' Aaron Bush consider the unusual antitrust situation that newspapers find themselves in. Asserting that the power Google
Has Cirrus Logic's Growth Just Begun?
Cirrus Logic (NASDAQ: CRUS) shareholders have enjoyed a great run recently, with the company's stock rising roughly 60% over the last 12 months. But Cirrus, which develops high-performance, low-power
6 Things You Didn't Know About PayPal Holdings, Inc.
PayPal (NASDAQ: PYPL) stock has been a hot performer in 2017. Year to date, shares are up an impressive 45%, trouncing the S&P 500's 10% return during the same period. The soaring stock price has
How to Invest in the Internet of Things
The Internet of Things, or IoT, has been a hot buzzword for years now, but it's only getting started. Here are some of the best ways to connect your investing portfolio to the sizzling connected
What to Look Out For When Honeywell International Reports Earnings
Honeywell International's (NYSE: HON) second quarter is shaping up to be a very interesting one for investors. In short, the company faces a mix of earnings headwinds and tailwinds, and it's hard to
Is Now the Time to Buy Chipotle Mexican Grill Stock?
Chipotle Mexican Grill (NYSE: CMG) stock is down almost 15% since management updated its guidance last month for the second quarter of 2017. It was close to the same guidance management gave in late
Is Aurinia Pharmaceuticals' Management Its Best Asset?
Richard Glickman was the founder and CEO of Aspreva Pharmaceuticals, a small company that he sold for $915 million in 2008 after it developed CellCept, a treatment that today is commonly used in lupus
Down 14.8%: Is Celldex Therapeutics Stock an Incredible Bargain?
Despite a widespread rally across the biotech landscape last month, the struggling clinical-stage cancer company Celldex Therapeutics (NASDAQ: CLDX) still managed to shed 14.8% of its value in